We have 4 of 19 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Treatment of MOGAD includes management of the acute episode and the use of chronic immunomodulatory therapy to prevent relapses and sequelae and, in selected cases, the use of chronic immunomodulatory therapy to prevent relapses and sequelae.
The disease associated with antibodies against myelin oligodendrocyte glycoprotein (MOGAD) is an inflammatory demyelinating disorder of the central nervous system, with acute disseminated encephalomyelitis in children, and optic neuritis and transverse myelitis more frequently observed in adults.
Evidence indicates that early initiation of high-efficacy disease-modifying therapies is associated with improved long-term outcomes.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
